• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    9/4/24 7:55:41 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MRAI alert in real time by email
    SC 13D/A 1 ea0213362-13da9lamend_marpai.htm AMENDMENT NO. 9 TO SCHEDULE 13D

     

     

    UNITED STATES

     SECURITIES AND EXCHANGE COMMISSION

     Washington, D.C. 20549

     

    SCHEDULE 13D

    (Amendment No. 9)

     

    Under the Securities Exchange Act of 1934

     

    MARPAI, INC.

    (Name of Issuer)

     

    Class A Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    571354 109

    (CUSIP Number)

     

    Damien Lamendola c/o Marpai, Inc.

    615 Channelside Drive, Suite 207

    Tampa, Florida 33602

    (646) 303-3483 

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    August 28, 2024

     (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b) for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 571354 109

     

    1

    NAMES OF REPORTING PERSONS

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Damien Lamendola

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐
    (b) ☒

    3

    SEC USE ONLY  

     

     

     
    4

    SOURCE OF FUNDS (See Instructions)

     

    PF

     
    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    7

    SOLE VOTING POWER

     

    210,000 (1)
    8

    SHARED VOTING POWER

     

    6,049,331

    9

    SOLE DISPOSITIVE POWER

     

    210,000(1)
    10

    SHARED DISPOSITIVE POWER

     

    6,049,331

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,049,331(1)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    44.0%(2)

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

     

    (1)Comprised of (i) 4,917,657 shares of Class A common stock, par value $0.0001 per share (“Common Stock”) of Marpai, Inc. (the“Issuer”) held directly by HillCour Investment Fund, LLC, of which Mr. Lamendola is the Manager, and over which he holds the voting and dispositive power, (ii) 931,674 shares of the Issuer’s Common Stock held directly by WellEnterprises USA, LLC, a wholly owned subsidiary of HillCour, Inc., which is wholly owned by HillCour Holdings LLC (f/k/a HillCour Holding Corporation) (“HillCour Holdings”), a corporation controlled by Mr. Lamendola, and Mr. Lamendola holds the voting and dispositive power over the securities held by WellEnterprises USA, LLC, (iii) 420,000 shares of Common Stock Restricted stock awards vesting over the next 2 years, held directly by HillCour Investment Fund, LLC, of which Mr. Lamendola is the Manager, and over which he holds the voting and dispositive power, (iv) 91,117 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $5.71 per share expiring on January 17, 2025 held directly by HillCour Investment Fund, LLC, of which Mr. Lamendola is the Manager, and over which he holds the voting and dispositive power, (v) 43,750 shares of the Issuer’s Common Stock issuable upon the exercise of options issued to Mr. Lamendola at an exercise price of $4.44, issued on June 14, 2022 and vesting monthly over a three year period, (vi) 18,750 shares of the Issuer’s Common Stock issuable upon the exercise of options issued to Mr. Lamendola at an exercise price of $4.44, issued on June 14, 2022 and vesting monthly over a four year period, and (vii) 210,000 shares of the Issuer’s Common Stock held by Mr. Lamendola.

     

    (2)Percentage is calculated based on 13,740,492 shares of Common Stock outstanding as of August 28, 2024.

     

    2

     

     

    SCHEDULE 13D

     

    CUSIP No. 571354 109

     

    1

    NAMES OF REPORTING PERSONS

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    HillCour Investment Fund, LLC 81-5352590

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☒
    (b) ☐

    3

    SEC USE ONLY  

     

     

     
    4

    SOURCE OF FUNDS (See Instructions)

     

    WC

     
    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    7

    SOLE VOTING POWER

     

    0
    8

    SHARED VOTING POWER

     

    4,917,657(1)(3)

    9

    SOLE DISPOSITIVE POWER

     

    0(3)
    10

    SHARED DISPOSITIVE POWER

     

    4,917,657

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,917,657(3)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    35.78%(2)

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    CO

     

    (3)Comprised of (i) 4,826,540 shares of Common Stock of the Issuer held directly by HillCour Investment Fund, LLC, of which Mr. Lamendola is the Manager, and over which he holds the voting and dispositive power, (ii) 420,000 shares of Common Stock Restricted stock awards vesting over the next 2 years, held directly by HillCour Investment Fund, LLC, of which Mr. Lamendola is the Manager, and over which he holds the voting and dispositive power, and (iii) 91,117 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $5.71 per share expiring on January 17, 2025 held directly by HillCour Investment Fund, LLC, of which Mr. Lamendola is the Manager, and over which he holds the voting and dispositive power.

     

    3

     

     

    SCHEDULE 13D

     

    CUSIP No. 571354 109

     

    1

    NAMES OF REPORTING PERSONS

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    WellEnterprises USA, LLC 46-0837544

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☒
    (b) ☐

    3

    SEC USE ONLY  

     

     

     
    4

    SOURCE OF FUNDS (See Instructions)

     

    WC

     
    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    7

    SOLE VOTING POWER

     

    931,674(4)
    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    931,674(4)
    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    931,674(4)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     

    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.78%(2)

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    CO

     

    (4)Comprised of 931,674 shares of the Issuer’s Common Stock held directly by WellEnterprises USA, LLC, a wholly owned subsidiary of HillCour, Inc., which is wholly owned by HillCour Holdings, a LLC controlled by Mr. Lamendola. Mr. Lamendola holds the voting and dispositive power over the securities held by WellEnterprises USA, LLC.

     

     

    4

     

     

    EXPLANATORY NOTE

     

    This Amendment No. 9 (“Amendment No. 9”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the “Commission”) on February 1, 2022, Amendment No. 1 to Schedule 13D filed on February 1, 2022, Amendment No. 2 to Schedule 13D filed on August 23, 2022, Amendment No. 3 to Schedule 13D filed on August 28, 2022, Amendment No. 4 to Schedule 13D filed on November 28, 2023, Amendment No. 5 to Schedule 13D filed on December 18, 2023, Amendment No. 6 to Schedule 13D filed on January 19, 2024, Amendment No. 7 to Schedule 13D filed on March 7, 2024 and Amendment No. 8 to Schedule 13D filed on May 29, 2024 (collectively, the “Schedule 13D”). Each Item below amends and supplements the information disclosed under the corresponding Item of the Schedule 13D. Capitalized terms used but not defined herein shall have the meanings attributed to them in the Schedule 13D. Except as otherwise set forth herein, this Amendment No. 9 does not modify any of the information previously reported by the Reporting Persons in the Schedule 13D.

     

    The purpose of this Schedule 13D filing is to update the ownership by Damien Lamendola, HillCour Investment Fund, LLC, and WellEnterprises USA, LLC (collectively the “Reporting Persons”) of the Issuer’s Common Stock.

     

    Except as specifically amended below, all other provisions of the Schedule 13D remain in effect.

     

    Item 2.Identity and Background

     

    Item 2 of the Schedule 13D is hereby amended and supplemented by inserting the following paragraph before the first paragraph thereof:

     

    On August 28, 2024, the Reporting Person purchased 1,351,351 shares of Common Stock of the Issuer at a purchase price of $0.481 per share. The Reporting Person paid such consideration using personal funds.

     

    Item 3.Source and Amount of Funds or Other Considerations

     

    Item 3 of the Schedule 13D is hereby amended and supplemented by inserting the following paragraph after the last paragraph thereof:

     

    The Source and Amount of Funds or Other Consideration for the purchase of the shares of Common Stock on August 28, 2024 is set forth in Item 2.

     

    Item 5.Interest in Securities of the Issuer

     

    Items 5(a) of the Schedule 13D are hereby amended and supplemented by the following paragraphs:

     

    (a)Damien Lamendola

     

    As of August 28, 2024, Damien Lamendola may be deemed to be the beneficial owner of: (1) 4,917,657 shares of the Issuer’s Common Stock held directly by HillCour Investment Fund, LLC (35.78% of the outstanding Common Stock), of which Mr. Lamendola is the Manager, and over which he holds the voting and dispositive power; (2) 931,674 shares of the Issuer’s Common Stock (6.78% of the outstanding Common Stock) held directly by WellEnterprises USA, LLC, a wholly owned subsidiary of HillCour, Inc., which is wholly owned by HillCour Holdings, a LLC controlled by Mr. Lamendola, and he holds the voting and dispositive power over the securities held by WellEnterprises USA, LLC; (3) 420,000 shares of Common Stock Restricted stock awards vesting over the next 2 years, held directly by HillCour Investment Fund, LLC, of which Mr. Lamendola is the Manager, and over which he holds the voting and dispositive power; (4) 91,117 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $5.71 per share expiring on January 17, 2025 held directly by HillCour Investment Fund, LLC (0.66% of the outstanding Common Stock), of which Mr. Lamendola is the Manager, and over which he holds the voting and dispositive power, (5) 43,750 shares of the Issuer’s Common Stock issuable upon the exercise of options issued to Mr. Lamendola at an exercise price of $4.44, issued on June 14, 2022 and vesting monthly over a three year period, (6) 18,750 shares of the Issuer’s Common Stock issuable upon the exercise of options issued to Mr. Lamendola at an exercise price of $4.44, issued on June 14, 2022 and vesting monthly over a four year period, and (7) 210,000 shares of the Issuer’s Common Stock owned by Mr. Lamendola.

     

    5

     

     

    (a) (b)HillCour Investment Fund, LLC

     

    As of August 28, 2024, HillCour Investment Fund, LLC may be deemed to be the beneficial owner of: (1) 4,917,657 shares of the Issuer’s Common Stock held directly by HillCour Investment Fund, LLC (35.78% of the outstanding Common Stock), and over which it holds the voting and dispositive power; (2) 420,000 shares of Common Stock Restricted stock awards vesting over the next 2 years, held directly by HillCour Investment Fund, LLC, of which Mr. Lamendola is the Manager, and over which he holds the voting and dispositive power; and (3) 91,117 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $5.71 per share expiring on January 17, 2025 held directly by HillCour Investment Fund, LLC (0.66% of the outstanding Common Stock), and over which it holds the voting and dispositive power.

     

    (a) (b)WellEnterprises USA, LLC

     

    As of December 18, 2023, WellEnterprises USA, LLC may be deemed to be the beneficial owner of 931,674 shares of the Issuer’s Common Stock which it holds directly (6.78% of the outstanding Common Stock), and over which it holds voting and dispositive power.

     

    Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    Item 6 of the Schedule 13D is hereby amended and supplemented by the following paragraphs:

     

    Except as described in the Explanatory Note, and as disclosed in the Schedule 13D, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons and any other person with respect to any securities of the Issuer, including, but not limited to transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

     

    Item 7.Material to Be Filed as Exhibits

     

    Exhibit 99.1   Warrant Agreement, dated April 1, 2021, by and between the Issuer and HillCour Investment Fund, LLC (incorporated by reference to Exhibit 4.55 to the Registration Statement on Form S-1 filed by the Issuer with the SEC on July 20, 2021).

     

    6

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated : September 4, 2024

     

    DAMIEN LAMENDOLA  
         
    By: /s/ Damien Lamendola  
    Name: Damien Lamendola  
         
    HILLCOUR INVESTMENT FUND, LLC  
         
    By: /s/ Damien Lamendola  
    Name: Damien Lamendola  
    Its: Manager  
         
    WELLENTERPRISES USA, LLC  
         
    By: /s/ Damien Lamendola  
    Name: Damien Lamendola  
    Its: Manager  

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

     

    7

     

    Get the next $MRAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MRAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS

      TAMPA, Fla., May 7, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, May 15 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q1 2025. The Company will report its first quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q1 Financial Results Conference Call Date: May 15, 2025 Time: 8:30 a.m. Eastern Time Call:    US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:    https://app.webinar.net/e6RGaxOgz3n Follow us on X.com and LinkedIn You may stream th

      5/7/25 4:03:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Marpai, Inc. to Present at the Planet MicroCap Showcase Las Vegas

      The investor conference is in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025 TAMPA, Fla., April 15, 2025 /PRNewswire/ -- Marpai, Inc. (OTCQX:MRAI),  a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and offers affordable, intelligent, healthcare solutions to self-funded employer health plans, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 5:30 PM (Local Time -PST). Marpai's CEO, Damien Lamendola and CFO, Steve Johnson will be hosting the presentation and answering ques

      4/15/25 10:49:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

      MARPAI EXHIBITS STRONG, ONGOING FINANCIAL IMPROVEMENT TAMPA, Fla., March 26, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans, today announced the financial results for the fourth quarter and fiscal year 2024. The Company expects to hold a webcast to discuss the results on March 27, 2025. Q4 2024 Financial Highlights: Net revenues were $6.6 million in Q4 2024, a decrease of $0.4 million, or 6.0% lower than Q3 2

      3/26/25 4:15:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Leadership Updates

    Live Leadership Updates

    See more
    • Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions

      STUART, Fla., Jan. 22, 2025 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a  competitively priced self-funded health plan to the market. By utilizing the strength of Vitable's Direct Primary Care (DPC), a health plan, and stop-loss coverage, Health In Tech seeks to offer low quotes on their eDIYBS platform, and to set an ambitious standard in affordability and efficiency. Vitable's enhanced primary care plan co

      1/22/25 5:00:00 PM ET
      $HIT
      $MRAI
      Specialty Insurers
      Finance
      Misc Health and Biotechnology Services
      Health Care
    • George Economou Files Definitive Proxy Statement and Sends Letter to Genco Shareholders

      Highlights Urgent Need for An Independent Director Perspective to Address Genco's Persistent Underperformance and Unlock Value for Shareholders Outlines Concerns with Chairman James Dolphin's Outsized Influence in the Genco Boardroom Urges Shareholders to Vote FOR the Election of GK Investor Nominee Robert Pons on the BLUE Universal Proxy Card and WITHHOLD on Genco Board Chairman James Dolphin GK Investor LLC ("GK"), an affiliate of George Economou that is an approximately 5.3% shareholder of Genco Shipping & Trading Limited ("Genco" or the "Company") (NYSE:GNK), today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connec

      4/18/24 1:07:00 PM ET
      $GNK
      $INSG
      $MRAI
      $SEAC
      Marine Transportation
      Consumer Discretionary
      Telecommunications Equipment
      Telecommunications
    • MARPAI HIRES JOHN POWERS AS PRESIDENT

      Accomplished Industry Veteran with Proven Track Record of Successful High Growth Operations to support Marpai's vision of Affordable, Intelligent, Healthcare NEW YORK, Jan. 12, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (NASDAQ:MRAI), an independent national Third-Party Administration company transforming the $22 billion TPA market supporting self-funded employer health plans, today announced the appointment of John Powers as the Company's President. Powers is an accomplished healthcare benefits executive with over 30 years' experience. Powers was previously CEO of Homestead Smart Health Plans. Powers brings deep operations knowledge and an extensive industry network devel

      1/12/24 8:30:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and COO Powers John Paul was granted 100,000 shares and bought $11,300 worth of shares (10,000 units at $1.13), increasing direct ownership by 73% to 260,000 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:15:20 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Chief Financial Officer Johnson Steve Andrew was granted 100,000 shares and bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 29% to 473,061 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:14:54 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Director Eitan Yaron was granted 5,000 shares and bought $124,999 worth of shares (110,619 units at $1.13), increasing direct ownership by 17% to 789,073 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:14:32 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    SEC Filings

    See more
    • SEC Form 10-K filed by Marpai Inc.

      10-K - Marpai, Inc. (0001844392) (Filer)

      3/26/25 7:30:28 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Marpai, Inc. (0001844392) (Filer)

      2/6/25 4:01:26 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - Marpai, Inc. (0001844392) (Filer)

      1/6/25 4:15:22 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Marpai Inc.

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      12/9/24 5:14:07 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Marpai Inc.

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      9/4/24 7:55:41 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      5/29/24 4:01:02 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Financials

    Live finance-specific insights

    See more
    • MARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS

      TAMPA, Fla., May 7, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, May 15 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q1 2025. The Company will report its first quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q1 Financial Results Conference Call Date: May 15, 2025 Time: 8:30 a.m. Eastern Time Call:    US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:    https://app.webinar.net/e6RGaxOgz3n Follow us on X.com and LinkedIn You may stream th

      5/7/25 4:03:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON MARCH 27, 2025 TO DISCUSS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

      TAMPA, Fla., March 20, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a technology platform company, operates as a national Third-Party Administrator (TPA) through its subsidiaries. We're transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans. The Company will host a conference call and webcast on Thursday, March 27 at 8:30 a.m. ET to present the Company's operational and financial highlights for 2024. The Company will report its fourth quarter and full year 2024 results on Wednesday after the market close. Event: Marpai 2024 Financial Results Conference Call Date: March 27, 2025 Time

      3/20/25 8:32:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON NOVEMBER 12, 2024 TO DISCUSS THIRD QUARTER 2024 FINANCIAL RESULTS

      TAMPA, Fla., Nov. 8, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a technology platform company, operates as a national Third-Party Administrator (TPA) through its subsidiaries. We're transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans. The Company will host a conference call and webcast on Tuesday, November 12 at 8:30 a.m. ET to present the Company's operational and financial highlights for its third quarter 2024. The Company will report its third quarter results on Monday after the market close. Event: Marpai Third Quarter Financial Results Conference Call Date: November 12, 20

      11/8/24 2:45:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Lamendola Damien was granted 600,000 shares (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      1/29/25 4:01:10 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • New insider Intelligent Fanatics Capital Management Llc claimed ownership of 3,729,414 shares (SEC Form 3)

      3 - Marpai, Inc. (0001844392) (Issuer)

      1/2/25 9:41:02 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • President and COO Powers John Paul was granted 100,000 shares and bought $11,300 worth of shares (10,000 units at $1.13), increasing direct ownership by 73% to 260,000 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:15:20 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care